Back to top
more

Palatin Technologies (PTN)

(Real Time Quote from BATS)

$1.84 USD

1.84
178,774

+0.02 (1.10%)

Updated Apr 16, 2024 02:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PTN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Palatin Technologies, Inc. [PTN]

Reports for Purchase

Showing records 1 - 20 ( 194 total )

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

02/28/2024

Company Report

Pages: 6

Does MELODY-1 Hit the Right Chord; We''ll See FDA Feedback; Target Lowered to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/15/2024

Company Report

Pages: 7

F2Q24 Results; A Year of Catalysts, But Eyes Are Fixed on Imminent DED Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/09/2024

Company Report

Pages: 7

Bright Pipeline Outlook in 2024; Embracing a Wave of Upcoming Data Updates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/20/2023

Company Report

Pages: 9

The Vyleesi Climax With Cash For the Effort; Focus on Phase 3 DED Data Soon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/22/2023

Industry Report

Pages: 9

Critical Near-Term Data Catalysts In Our Universe Represent Thesis Definers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/14/2023

Company Report

Pages: 9

F1Q24 Results; Looking For Sweet Music Shortly on Pivotal DED Study Read Out; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/18/2023

Company Report

Pages: 8

Uniting Melanocortin Receptor and GLP-1 Therapies For Obesity and Diabetes

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/16/2023

Company Report

Pages: 9

Preclinical Data Further Bolster PL8177''s Potential in UC; Phase 2 UC Interim Data in 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/28/2023

Company Report

Pages: 8

FY2023 Results; Pivotal DED Data Soon; Vyleesi Continues to Grow

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/07/2023

Daily Note

Pages: 9

MELODY-1 Completes Enrollment; Top-Line Data in 4Q23 Represents Major Catalyst

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/10/2023

Company Report

Pages: 10

Clinical Pipeline Grows in Earnest

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/08/2023

Company Report

Pages: 10

Vyleesi Strengthens Foothold in Asian Marketplace; First China Sale and Phase 3 HSDD Enrollment Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/07/2023

Daily Note

Pages: 8

New Partnership With UpScriptHealth Amplifies Vyleesi Access and Awareness

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/30/2023

Company Report

Pages: 9

Targeting Podocytes to Resolve Kidney Injury; Preclinical Data Support MC1r AgonistsÂ’ Ability to Treat DN

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/16/2023

Company Report

Pages: 8

F3Q23 Results; A Melanocortin Medley of Data Readouts to Come; Reiterate Top Pick

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/09/2023

Company Report

Pages: 7

Preclinical Data Spotlight P8177 in IBD; Phase 2 Top-Line Data in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/09/2023

Company Report

Pages: 9

Recipe for Success; KOL Event Highlights PL9643 and Clinical Strategy Ahead of Full MELODY-1 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

04/27/2023

Company Report

Pages: 8

A Sight For Sore Eyes; PL9643 Exhibits Initial Pivotal Promise in DED; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

04/25/2023

Company Report

Pages: 8

PL9588 Shows Initial Signs of Efficacy in Glaucoma Models; Vyleesi Traction Grows

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/13/2023

Company Report

Pages: 11

Important Preview: PL9643 Seeks to Strike the Right Chord in DED; MELODY-1 Top-Line Data Mid-23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party